About Qutenza®
Qutenza® is indicated for the management of neuropathic pain associated with postherpetic neuralgia (PHN).1
A single, 1-hour, localized treatment can provide 3 months of relief from pain associated with PHN.1
The active ingredient in Qutenza® is prescription-strength capsaicin. Capsaicin is a naturally occurring compound found in chili peppers that gives them their heat sensation.1
Qutenza® harnesses the power of capsaicin in a localized, dermal delivery system that targets the nerves in the skin.1
Qutenza® is applied to the painful site by a physician or a healthcare professional under the close supervision of a physician. It is the first and only prescription-strength capsaicin product.1
Qutenza® is non-narcotic and is unlikely to have drug-drug interactions. It can be used alone or with other pain medications.1
Single, 1-hour, localized treatment can provide 3 months of relief from pain associated with postherpetic neuralgia.
Reference:
Qutenza® Prescribing Information.
Request Qutenza® TRAINING
Call 877-900-6479
Order Qutenza®
Support For Your Practice
Indication: Qutenza® (capsaicin) 8% patch is indicated for the management of neuropathic pain associated with postherpetic neuralgia.
IMPORTANT SAFETY INFORMATION
Only physicians or healthcare professionals under the close supervision of a physician are to administer Qutenza®.
Contraindications: None.
Warnings and Precautions:
- Do not use on face or scalp.
- Aerosolization of capsaicin can occur and inhalation may result in coughing or sneezing.
- If skin not intended to be treated comes into contact with Qutenza®, clean area using Cleansing Gel.
- Patients may experience substantial procedural pain. Prepare to treat pain with local cooling (such as a cold pack) and/or appropriate analgesic medication.
- Transient increases in blood pressure may occur during and shortly after the Qutenza® treatment. In clinical trials, blood pressure changes were associated with treatment-related increases in pain. Monitor blood pressure and provide adequate support for treatment-related pain. Patients with unstable or poorly controlled hypertension or a recent history of cardiovascular or cerebrovascular events may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating Qutenza® treatment.
Adverse Reactions: In clinical trials, serious adverse reactions included application-associated pain and increase in blood pressure. The most common adverse reactions (≥ 5% and greater than control) were application-site erythema, application-site pain, application-site pruritus, and application-site papules.
For additional information, please click here for full Prescribing Information.
©NeurogesX, Inc. 2010. All Rights Reserved. ®marks owned by NeurogesX, Inc. Q2010032-13 110453